Here's Why You Should Retain OPK Stock in Your Portfolio for NowZacks Investment Research • Wednesday
OPKO Health Reports Third Quarter 2026 Business Highlights and Financial ResultsGlobeNewsWire • 11/04/26
OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026GlobeNewsWire • 10/28/26
OPKO Health's OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for AcromegalyGlobeNewsWire • 10/27/26
OPKO Health to Sell Select BioReference Assets to Labcorp for $722MZacks Investment Research • 10/16/26
Penske Automotive, OPKO Health, Ericsson And Other Big Stocks Moving Higher On ThursdayBenzinga • 10/15/26
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference HealthPRNewsWire • 10/15/26
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare ConferenceGlobeNewsWire • 09/08/26
OPK Raises $125 Million Against Royalties: What Investors Should KnowZacks Investment Research • 08/19/26
Is OPK Worth Buying as Valuation Meets Improving Business Trends?Zacks Investment Research • 08/19/26
OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?Zacks Investment Research • 08/19/26
OPKO Health Secures $125 Million Financing Against Mazdutide RoyaltiesZacks Investment Research • 08/18/26
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty InterestsGlobeNewsWire • 08/13/26